REG - Hemogenyx Pharma Plc - Issue of Equity

Hemogenyx PharmaceuticalsAnnouncement

18/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0124Ma&default-theme=true

RNS Number : 0124M  Hemogenyx Pharmaceuticals PLC  18 December 2025

18 December 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Issue of Equity arising from the Exercise of Warrants, Restricted Stock Unit
Award and Deed of Variation And Total Voting Rights

 

Introduction

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has issued and
allotted an aggregate of 123,377 new Ordinary Shares of 1p each ("Ordinary
Shares") in the Company for the reasons set out in this announcement.

Warrant Shares

The Company has received notices to exercise warrants over 105,556 new
Ordinary Shares at an exercise price of £1.80 (the "Warrant Shares") raising
£190,000 for the Company.

Restricted Stock Units

The Company also announces the vesting of 6,000 Restricted Stock Units, the
grant of which was announced on 29 October 2025. The Company has therefore
issued and allotted an aggregate of 6,000 new Ordinary Shares (the "RSU
Shares").

Deed of Variation

Further, the Company has issued and allotted 11,821 new Ordinary Shares
further to obligations imposed on it under the terms of a Deed of Variation
entered into by the Company on 16 September 2025 (the "Variation Shares").
  The Variation Shares are being issued at a price of £8.84 per Variation
Share.

Admission and Total Voting Rights

Application will be made for the Warrant Shares, the RSU Shares and the
Variation Shares (which will rank pari passu in all respects with the existing
Ordinary Shares of the Company), to be admitted to the FCA official list and
to trading on the equity shares (transition) category of the Official List
maintained by the FCA and to trading on the main market for listed securities
of the LSE, which is expected to occur on or around 8.00 a.m. on 23 December
2025 ("Admission").

Upon Admission, the total number of issued shares and the total number of
voting rights in the Company will be 6,041,255.

The above figure of 6,041,255 should be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials
proceed.

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 AlbR Capital Limited                                            Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEDDLFFELLLFBB



            Copyright 2019 Regulatory News Service, all rights reserved